Riluzole

利鲁唑

Report date: 2026/04/13 20:02:18
NME

Base Information

Drug NameRiluzole
Drug Alias NameriluzolumriluzoleriluzolTeglutikRilutek +[10
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel alpha subunit modulators
TargetsSodium channel alpha subunit
Therapy Area/IndicationsSkin MelanomaSolid tumoursStress Disorders, Post-Traumatic +[30
Global Approved IndicationsAmyotrophic Lateral Sclerosis
Approved Indications in ChinaAmyotrophic Lateral Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date1995/12/12
Country/TerritoryCzechiaCanadaUnited States +[11
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active IndicationsAtrial FibrillationMotor Neuron DiseaseAmyotrophic Lateral Sclerosis +[13
Inactive IndicationsSkin MelanomaSolid tumoursStress Disorders, Post-Traumatic +[17

Other Information

ATC CodeN07XX02